Centre Asset Management LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 90,520 shares of the company’s stock after selling 1,020 shares during the quarter. Johnson & Johnson makes up approximately 3.1% of Centre Asset Management LLC’s portfolio, making the stock its 10th biggest position. Centre Asset Management LLC’s holdings in Johnson & Johnson were worth $11,769,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of JNJ. Curbstone Financial Management Corp lifted its stake in Johnson & Johnson by 99.1% in the third quarter. Curbstone Financial Management Corp now owns 30,400 shares of the company’s stock valued at $3,952,000 after buying an additional 15,134 shares during the last quarter. Bogart Wealth LLC lifted its stake in Johnson & Johnson by 6.7% in the second quarter. Bogart Wealth LLC now owns 6,006 shares of the company’s stock valued at $795,000 after buying an additional 378 shares during the last quarter. MPS Loria Financial Planners LLC purchased a new stake in Johnson & Johnson in the second quarter valued at approximately $1,415,000. W. E. Donoghue & Co. LLC purchased a new stake in Johnson & Johnson in the second quarter valued at approximately $16,120,000. Finally, Pinnacle Family Advisors LLC purchased a new stake in Johnson & Johnson in the second quarter valued at approximately $209,000. Hedge funds and other institutional investors own 65.70% of the company’s stock.

A number of brokerages have weighed in on JNJ. Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. Citigroup began coverage on Johnson & Johnson in a research note on Monday, September 25th. They issued a “neutral” rating and a $140.00 price objective for the company. BMO Capital Markets reiterated a “positive” rating and issued a $152.00 price objective (up previously from $145.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Jefferies Group boosted their price objective on Johnson & Johnson from $157.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, October 16th. Finally, Royal Bank of Canada boosted their price objective on Johnson & Johnson from $144.00 to $147.00 and gave the company an “outperform” rating in a research note on Wednesday, October 18th. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and a consensus price target of $145.04.

Johnson & Johnson (NYSE JNJ) opened at $141.80 on Tuesday. The stock has a market capitalization of $382,721.66, a P/E ratio of 19.95, a PEG ratio of 2.90 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a twelve month low of $110.76 and a twelve month high of $144.35.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. The business had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.68 earnings per share. sell-side analysts forecast that Johnson & Johnson will post 7.28 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th were issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.37%. The ex-dividend date was Monday, November 27th. Johnson & Johnson’s payout ratio is currently 58.33%.

WARNING: “Johnson & Johnson (JNJ) Position Trimmed by Centre Asset Management LLC” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.watchlistnews.com/johnson-johnson-jnj-position-trimmed-by-centre-asset-management-llc/1772863.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.